Leiomyosarcoma (LMS)

Also known as: LMS - Leiomyosarcoma / Leiomyosarcomas / Leiomyosarcoma / [M]Leiomyosarcoma NOS (morphologic abnormality) / Leiomyosarcoma NOS / Leiomyomosarcoma, no subtype (morphologic abnormality) / Leiomyosarcoma (disorder)

Drug	Drug Name	Drug Description
DB00398	Sorafenib	A kinase inhibitor used to treat unresectable liver carcinoma, advanced renal carcinoma, and differentiated thyroid carcinoma.

Drug	Drug Name	Target	Type
DB00398	Sorafenib	Serine/threonine-protein kinase B-raf	target
DB00398	Sorafenib	Receptor-type tyrosine-protein kinase FLT3	target
DB00398	Sorafenib	RAF proto-oncogene serine/threonine-protein kinase	target
DB00398	Sorafenib	Vascular endothelial growth factor receptor 3	target
DB00398	Sorafenib	Platelet-derived growth factor receptor beta	target
DB00398	Sorafenib	Mast/stem cell growth factor receptor Kit	target
DB00398	Sorafenib	Vascular endothelial growth factor receptor 2	target
DB00398	Sorafenib	Cytochrome P450 3A4	enzyme
DB00398	Sorafenib	UDP-glucuronosyltransferase 1-9	enzyme
DB00398	Sorafenib	Cytochrome P450 2B6	enzyme
DB00398	Sorafenib	Cytochrome P450 2C8	enzyme
DB00398	Sorafenib	Cytochrome P450 3A5	enzyme
DB00398	Sorafenib	Cytochrome P450 3A7	enzyme
DB00398	Sorafenib	Cytochrome P450 2C9	enzyme
DB00398	Sorafenib	Multidrug resistance-associated protein 4	transporter
DB00398	Sorafenib	P-glycoprotein 1	transporter
DB00398	Sorafenib	Canalicular multispecific organic anion transporter 1	transporter
DB00398	Sorafenib	ATP-binding cassette sub-family G member 2	transporter
DB00398	Sorafenib	Cytochrome P450 1A2	enzyme
DB00398	Sorafenib	Cytochrome P450 2C19	enzyme
DB00398	Sorafenib	Cytochrome P450 2D6	enzyme
DB00398	Sorafenib	UDP-glucuronosyltransferase 1-1	enzyme
DB00398	Sorafenib	RalA-binding protein 1	transporter
DB00398	Sorafenib	Fibroblast growth factor receptor 1	target
DB00398	Sorafenib	Proto-oncogene tyrosine-protein kinase receptor Ret	target
DB00398	Sorafenib	Vascular endothelial growth factor receptor 1	target
DB00398	Sorafenib	Solute carrier organic anion transporter family member 1B1	transporter

Drug	Drug Name	Phase	Status	Count
DB11945	Avelumab	1	Active Not Recruiting	1
DB00851	Dacarbazine	1	Active Not Recruiting	1
DB00997	Doxorubicin	1	Withdrawn	1
DB00441	Gemcitabine	1	Completed	1
DB09035	Nivolumab	1	Active Not Recruiting	1
DB06043	Olaratumab	1	Withdrawn	1
DB09037	Pembrolizumab	1	Terminated	1
DB11942	Selinexor	1	Recruiting	1
DB05109	Trabectedin	1	Completed	1
DB05109	Trabectedin	1	Withdrawn	1
DB18080	Unesbulin	1	Active Not Recruiting	1
DB18052	VMD-928	1	Recruiting	1
DB17520	Vimseltinib	1	Active Not Recruiting	1
DB14707	Cemiplimab	1 / 2	Recruiting	1
DB01248	Docetaxel	1 / 2	Recruiting	1
DB01248	Docetaxel	1 / 2	Terminated	1
DB00997	Doxorubicin	1 / 2	Active Not Recruiting	1
DB08871	Eribulin	1 / 2	Active Not Recruiting	1
DB00441	Gemcitabine	1 / 2	Terminated	1
DB09078	Lenvatinib	1 / 2	Active Not Recruiting	1
DB17116	Ontorpacept	1 / 2	Active Not Recruiting	1
DB06589	Pazopanib	1 / 2	Terminated	1
DB05109	Trabectedin	1 / 2	Recruiting	1
DB11794	Berzosertib	2	Completed	1
DB00112	Bevacizumab	2	Completed	2
DB00958	Carboplatin	2	Completed	1
DB04849	Cediranib	2	Active Not Recruiting	1
DB12250	Cixutumumab	2	Completed	1
DB00851	Dacarbazine	2	Completed	1
DB00851	Dacarbazine	2	Recruiting	2
DB03619	Deoxycholic acid	2	Terminated	1
DB01234	Dexamethasone	2	Completed	1
DB00380	Dexrazoxane	2	Completed	1
DB09077	Dinutuximab	2	Recruiting	1
DB01248	Docetaxel	2	Completed	3
DB01248	Docetaxel	2	Withdrawn	2
DB00997	Doxorubicin	2	Completed	3
DB00997	Doxorubicin	2	Recruiting	1
DB11714	Durvalumab	2	Active Not Recruiting	1
DB16047	Elraglusib	2	Withdrawn	2
DB08871	Eribulin	2	Active Not Recruiting	1
DB12091	Gadolinium	2	Recruiting	1
DB00441	Gemcitabine	2	Completed	4
DB00441	Gemcitabine	2	Recruiting	2
DB00441	Gemcitabine	2	Withdrawn	2
DB14865	Human interleukin-2	2	Recruiting	1
DB01006	Letrozole	2	Completed	1
DB01006	Letrozole	2	Terminated	1
DB09035	Nivolumab	2	Active Not Recruiting	2
DB09074	Olaparib	2	Active Not Recruiting	1
DB16269	Onfekafusp alfa	2	Recruiting	1
DB06589	Pazopanib	2	Completed	1
DB17284	Pelareorep	2	Completed	1
DB09037	Pembrolizumab	2	Active Not Recruiting	1
DB06233	Ridaforolimus	2	Completed	1
DB12332	Rucaparib	2	Active Not Recruiting	1
DB00398	Sorafenib	2	Completed	1
DB01268	Sunitinib	2	Completed	1
DB17072	Tabelecleucel	2	Recruiting	1
DB13896	Talimogene laherparepvec	2	Active Not Recruiting	1
DB05109	Trabectedin	2	Completed	3
DB05109	Trabectedin	2	Recruiting	1
DB02546	Vorinostat	2	Terminated	1
DB00399	Zoledronic acid	2	Recruiting	1
DB00531	Cyclophosphamide	2 / 3	Active Not Recruiting	1
DB00851	Dacarbazine	2 / 3	Recruiting	1
DB00694	Daunorubicin	2 / 3	Active Not Recruiting	1
DB00997	Doxorubicin	2 / 3	Active Not Recruiting	1
DB00997	Doxorubicin	2 / 3	Recruiting	1
DB01181	Ifosfamide	2 / 3	Active Not Recruiting	1
DB12674	Lurbinectedin	2 / 3	Recruiting	1
DB06589	Pazopanib	2 / 3	Active Not Recruiting	1
DB18080	Unesbulin	2 / 3	Recruiting	1
DB11885	Anlotinib	3	Active Not Recruiting	1
DB00851	Dacarbazine	3	Active Not Recruiting	1
DB05109	Trabectedin	3	Withdrawn	1
DB00445	Epirubicin	Not Available	Recruiting	1
DB08896	Regorafenib	Not Available	Recruiting	1
DB17072	Tabelecleucel	Not Available	No Longer Available	1
DB00853	Temozolomide	Not Available	Recruiting	1